272 related articles for article (PubMed ID: 31342534)
1. Abnormalities of mucosal serotonin metabolism and 5-HT
Gunn D; Garsed K; Lam C; Singh G; Lingaya M; Wahl V; Niesler B; Henry A; Hall IP; Whorwell P; Spiller R
Aliment Pharmacol Ther; 2019 Sep; 50(5):538-546. PubMed ID: 31342534
[TBL] [Abstract][Full Text] [Related]
2. Treatment of irritable bowel syndrome with diarrhoea using titrated ondansetron (TRITON): study protocol for a randomised controlled trial.
Gunn D; Fried R; Lalani R; Farrin A; Holloway I; Morris T; Olivier C; Kearns R; Corsetti M; Scott M; Farmer A; Emmanuel A; Whorwell P; Yiannakou Y; Sanders D; Mclaughlin J; Kapur K; Eugenicos M; Akbar A; Trudgill N; Houghton L; Dinning PG; Ford AC; Aziz Q; Spiller R
Trials; 2019 Aug; 20(1):517. PubMed ID: 31429811
[TBL] [Abstract][Full Text] [Related]
3. Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls.
Kumar S; Ranjan P; Mittal B; Ghoshal UC
J Gastrointestin Liver Dis; 2012 Mar; 21(1):31-8. PubMed ID: 22457857
[TBL] [Abstract][Full Text] [Related]
4. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1.
Shiotani A; Kusunoki H; Ishii M; Imamura H; Manabe N; Kamada T; Hata J; Merchant JL; Haruma K
Neurogastroenterol Motil; 2015 Jan; 27(1):82-91. PubMed ID: 25428414
[TBL] [Abstract][Full Text] [Related]
5. Targeting the 5-HT(3) receptor in the treatment of irritable bowel syndrome.
Spiller RC
Curr Opin Pharmacol; 2011 Feb; 11(1):68-74. PubMed ID: 21398180
[TBL] [Abstract][Full Text] [Related]
6. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea.
Garsed K; Chernova J; Hastings M; Lam C; Marciani L; Singh G; Henry A; Hall I; Whorwell P; Spiller R
Gut; 2014 Oct; 63(10):1617-25. PubMed ID: 24334242
[TBL] [Abstract][Full Text] [Related]
7. Identification of a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes.
Grasberger H; Chang L; Shih W; Presson AP; Sayuk GS; Newberry RD; Karagiannides I; Pothoulakis C; Mayer E; Merchant JL
Am J Gastroenterol; 2013 Nov; 108(11):1766-74. PubMed ID: 24060757
[TBL] [Abstract][Full Text] [Related]
8. Gender Differences in Serotonin Signaling in Patients with Diarrhea-predominant Irritable Bowel Syndrome.
Katsumata R; Shiotani A; Murao T; Ishii M; Fujita M; Matsumoto H; Haruma K
Intern Med; 2017; 56(9):993-999. PubMed ID: 28458330
[TBL] [Abstract][Full Text] [Related]
9. Mucosal Serotonin Reuptake Transporter Expression in Irritable Bowel Syndrome Is Modulated by Gut Microbiota Via Mast Cell-Prostaglandin E2.
Gao J; Xiong T; Grabauskas G; Owyang C
Gastroenterology; 2022 Jun; 162(7):1962-1974.e6. PubMed ID: 35167867
[TBL] [Abstract][Full Text] [Related]
10. Serotonin transporter gene promoter region polymorphisms and serotonin transporter expression in the colonic mucosa of irritable bowel syndrome patients.
Wang YM; Chang Y; Chang YY; Cheng J; Li J; Wang T; Zhang QY; Liang DC; Sun B; Wang BM
Neurogastroenterol Motil; 2012 Jun; 24(6):560-5, e254-5. PubMed ID: 22435794
[TBL] [Abstract][Full Text] [Related]
11. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome.
Coates MD; Mahoney CR; Linden DR; Sampson JE; Chen J; Blaszyk H; Crowell MD; Sharkey KA; Gershon MD; Mawe GM; Moses PL
Gastroenterology; 2004 Jun; 126(7):1657-64. PubMed ID: 15188158
[TBL] [Abstract][Full Text] [Related]
12. Comparison of 5-hydroxytryptophan signaling pathway characteristics in diarrhea-predominant irritable bowel syndrome and ulcerative colitis.
Yu FY; Huang SG; Zhang HY; Ye H; Chi HG; Zou Y; Lv RX; Zheng XB
World J Gastroenterol; 2016 Mar; 22(12):3451-9. PubMed ID: 27022227
[TBL] [Abstract][Full Text] [Related]
13. Serotonin type 3 receptor subunit gene polymorphisms associated with psychosomatic symptoms in irritable bowel syndrome: A multicenter retrospective study.
Berens S; Dong Y; Fritz N; Walstab J; D'Amato M; Zheng T; Wahl V; Boekstegers F; Bermejo JL; Martinez C; Schmitteckert S; Clevers E; Engel F; Gauss A; Herzog W; Spiller R; Goebel-Stengel M; Mönnikes H; Andresen V; Thomas F; Keller J; Pehl C; Stein-Thöringer C; Clarke G; Dinan TG; Quigley EM; Sayuk G; Simrén M; Tesarz J; Rappold G; van Oudenhove L; Schaefert R; Niesler B
World J Gastroenterol; 2022 Jun; 28(21):2334-2349. PubMed ID: 35800179
[TBL] [Abstract][Full Text] [Related]
14. Determination of genotype combinations that can predict the outcome of the treatment of alcohol dependence using the 5-HT(3) antagonist ondansetron.
Johnson BA; Seneviratne C; Wang XQ; Ait-Daoud N; Li MD
Am J Psychiatry; 2013 Sep; 170(9):1020-31. PubMed ID: 23897038
[TBL] [Abstract][Full Text] [Related]
15. Trypsinogen IV, serotonin transporter transcript levels and serotonin content are increased in small intestine of irritable bowel syndrome patients.
Kerckhoffs AP; Ter Linde JJ; Akkermans LM; Samsom M
Neurogastroenterol Motil; 2008 Aug; 20(8):900-7. PubMed ID: 18363639
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.
Zheng Y; Yu T; Tang Y; Xiong W; Shen X; Jiang L; Lin L
PLoS One; 2017; 12(3):e0172846. PubMed ID: 28291778
[TBL] [Abstract][Full Text] [Related]
17. The alternative serotonin transporter promoter P2 impacts gene function in females with irritable bowel syndrome.
Mohr S; Fritz N; Hammer C; Martínez C; Berens S; Schmitteckert S; Wahl V; Schmidt M; Houghton LA; Goebel-Stengel M; Kabisch M; Götze D; Milovač I; D'Amato M; Zheng T; Röth R; Mönnikes H; Engel F; Gauss A; Tesarz J; Raithel M; Andresen V; Frieling T; Keller J; Pehl C; Stein-Thöringer C; Clarke G; Kennedy PJ; Cryan JF; Dinan TG; Quigley EMM; Spiller R; Beltrán C; Madrid AM; Torres V; Pérez de Arce E; Herzog W; Mayer EA; Sayuk G; Gazouli M; Karamanolis G; Kapur-Pojskič L; Bustamante M; Rabionet R; Estivil X; Franke A; Lieb W; Boeckxstaens G; Wouters MM; Simrén M; Rappold GA; Vicario M; Santos J; Schaefert R; Lorenzo-Bermejo J; Niesler B
J Cell Mol Med; 2021 Aug; 25(16):8047-8061. PubMed ID: 34165249
[TBL] [Abstract][Full Text] [Related]
18. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.
Chey WD; Cash BD
Expert Opin Investig Drugs; 2005 Feb; 14(2):185-93. PubMed ID: 15757394
[TBL] [Abstract][Full Text] [Related]
19. The HTR3A polymorphism c. -42C>T is associated with amygdala responsiveness in patients with irritable bowel syndrome.
Kilpatrick LA; Labus JS; Coveleskie K; Hammer C; Rappold G; Tillisch K; Bueller JA; Suyenobu B; Jarcho JM; McRoberts JA; Niesler B; Mayer EA
Gastroenterology; 2011 Jun; 140(7):1943-51. PubMed ID: 21420406
[TBL] [Abstract][Full Text] [Related]
20. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.
Cremon C; Carini G; Wang B; Vasina V; Cogliandro RF; De Giorgio R; Stanghellini V; Grundy D; Tonini M; De Ponti F; Corinaldesi R; Barbara G
Am J Gastroenterol; 2011 Jul; 106(7):1290-8. PubMed ID: 21427712
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
